Commentary Open Access
Volume 7 | Issue 1 | DOI: https://doi.org/10.33696/haematology.7.080
Identifying Predictive Biomarkers for Immunotherapy: The Need for Minimally Invasive, Inexpensive, Broadly Applicable across Cancer Type, Pharmacodynamic Biomarkers
Simone Anfossi1,2,3,*
- 1Present address: Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- 2Immunology Program, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- 3Cancer Biology Program, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Corresponding Author
Simone Anfossi, sanfossi@mdanderson.org
Received Date: April 06, 2026
Accepted Date: July 27, 2026
Anfossi S. Identifying Predictive Biomarkers for Immunotherapy: The Need for Minimally Invasive, Inexpensive, Broadly Applicable Across Cancer Type, Pharmacodynamic Biomarkers. J Clin Haematol. 2026;7(1):65–71.
Copyright: © 2026 Anfossi S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Deubiquitinase as Potential Targets for Cancer Immunotherapy
During the last few decades, immunotherapy is considered to be an important approach to help our immune system to fight various kinds of diseases, such as tumor. Sometimes, it works very well for some types of cancers, for example: bladder cancer, colorectal cancer, breast cancer and lymphoma.
CTLA-4 and PD-L1 or PD-1 Pathways: Immune Checkpoint Inhibitors and Cancer Immunotherapy
The immune system developed certain checks and balance to control or inhibit the reactivity against normal cells of the body. Uncontrolled immune responses to the non-self entities such as bacteria, viruses, parasites, or mutated self-antigens can cause an inflammatory reaction and autoimmune diseases.
Cancer Nanomedicine: Strategies to Enhance Tumor Delivery and Immunotherapy
Cancer nanomedicine was originally developed for more efficient delivery of chemotherapeutic agents into tumor, and has been extensively employed as a therapeutic for cancer treatment owing to its unique features in drug delivery, diagnosis and imaging, as well as the therapeutic nature of some nanomaterials themselves.
Targeting "Do Not Eat Me" Signal CD47 in Cancer Immunotherapy
Cells of the innate and adaptive arm of the immune system including macrophages, natural killer (NK) cells, neutrophils, T cells, and B cells, etc. are crucial for the maintenance of the body’s homeostatic balance and prevention of multiple diseases including cancer.
Gemcitabine in the Era of Cancer Immunotherapy
Gemcitabine is a synthetic pyrimidine nucleoside analogue which is administered intravenously as a chemotherapeutic to treat numerous cancers. Gemcitabine requires transport into cells and activation by phosphorylation, the resulting gemcitabine triphosphate is incorporated into newly synthesized DNA during cell division, inhibiting further DNA synthesis and causing cell death. Gemcitabine is used to treat cancers including those of the pancreas, lung, breast, colon, and ovary either as first or second line treatments as a single agent or in combination.